Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.
Inspection Record
LCC Ltd. — FDA 483 Findings
Inspectors Arsen Karapetyan · Brittny C CargoThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in- process material and the drug product.
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.
The quality control unit lacks responsibility to approve all procedures or specifications impacting on the identity, strength, quality and purity of drug products.
Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.
Batch production and control records do not include complete information relating to the production and control of each batch.
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design, of adequate size and suitably located to facilitate operations for its intended use and cleaning and maintenance.
Records associated with drug product components, production, control and distribution and within the retention period for such records, were not made readily available for authorized inspection.
Procedures for the cleaning and maintenance of equipment are deficient regarding sufficient detail of the methods, equipment, and materials used in the cleaning and maintenance operation, and the methods of disassembly and reassembling equipment as necessary to assure proper cleaning and maintenance.
Individuals responsible for supervising the manufacture, processing, packing and holding of a drug product lack the education, training and experience to perform their assigned functions in such a manner as to assure the drug product has the safety, identity, strength, quality and purity that it purports or is represented to possess.
Complaint records are deficient in that they do not include the findings of the investigation and follow- up.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Shimoga Chemicals2026-01-23 · US FDASimilar to finding 6 Batch production and control records do not include complete information relating to the production and control of each batch.
- VitaCare Labs Inc.2025-05-16 · US FDASimilar to finding 6 Batch production and control records do not include complete information relating to the production and control of each batch.
- Granules Pharmaceuticals Inc.2026-04-03 · US FDASimilar to finding 6 Batch production and control records do not include complete information relating to the production and control of each batch.
- McNeil Consumer Healthcare2015-07-23 · US FDASimilar to finding 2 control procedures are not established which monitor the output and validate the preformance of those manufacturing processes that may be reponsible for…
- Wiley Chemists, Inc.2015-07-10 · US FDASimilar to finding 2 Control procedures are not estabJished which monitor the output and validate the perfonnance ofthose manufacturing processes that may be responsible for…
A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.